Literature DB >> 19711119

Non-motor symptoms in Parkinson's disease.

Ariane Park1, Mark Stacy.   

Abstract

Parkinson's disease is a hypokinetic movement disorder with cardinal motor features of bradykinesia, resting tremor and rigidity. However, non-motor symptoms, such as cognitive, neuropsychiatric, sleep, autonomic and sensory disturbances are gaining increasing attention. These non-motor symptoms may be intrinsic to the disease pathology or may be results of treatment with dopaminergic agents. Given that most, if not all, patients with Parkinson's disease will experience non-motor symptoms, it is important to be sensitive to these phenomena, especially since some non-motor signs may precede motor impairment. Treatment may include interventions independent of traditional, dopaminergic anti-Parkinson therapy or may be tailored to increase or reduce dopamine responsiveness of the symptom.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19711119     DOI: 10.1007/s00415-009-5240-1

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  58 in total

1.  Nighttime sleep problems and daytime sleepiness in Parkinson's disease.

Authors:  Dagmar Verbaan; Stephanie M van Rooden; Martine Visser; Johan Marinus; Jacobus J van Hilten
Journal:  Mov Disord       Date:  2008-01       Impact factor: 10.338

Review 2.  Integrative control of the lower urinary tract: preclinical perspective.

Authors:  William C de Groat
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

Review 3.  The discovery of the pressor effect of DOPS and its blunting by decarboxylase inhibitors.

Authors:  H Kaufmann
Journal:  J Neural Transm Suppl       Date:  2006

4.  SSRIs do not worsen Parkinson's disease: evidence from an open-label, prospective study.

Authors:  G Dell'Agnello; R Ceravolo; A Nuti; G Bellini; A Piccinni; C D'Avino; L Dell'Osso; U Bonuccelli
Journal:  Clin Neuropharmacol       Date:  2001 Jul-Aug       Impact factor: 1.592

5.  Effect of tegaserod on gut transit in male and female subjects.

Authors:  L Degen; C Petrig; D Studer; S Schroller; C Beglinger
Journal:  Neurogastroenterol Motil       Date:  2005-12       Impact factor: 3.598

6.  Update on the pharmacology of REM sleep behavior disorder.

Authors:  Jean-François Gagnon; Ronald B Postuma; Jacques Montplaisir
Journal:  Neurology       Date:  2006-09-12       Impact factor: 9.910

7.  Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study.

Authors:  D Aarsland; K Laake; J P Larsen; C Janvin
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-06       Impact factor: 10.154

8.  Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease.

Authors:  Alan Breier; Virginia K Sutton; Peter D Feldman; Deborah L Kadam; Iris Ferchland; Padraig Wright; Joseph H Friedman
Journal:  Biol Psychiatry       Date:  2002-09-01       Impact factor: 13.382

9.  Sodium oxybate for excessive daytime sleepiness in Parkinson disease: an open-label polysomnographic study.

Authors:  William G Ondo; Thomas Perkins; Todd Swick; Keith L Hull; J Ernesto Jimenez; Tippy S Garris; Daniel Pardi
Journal:  Arch Neurol       Date:  2008-10

10.  Macrogol for the treatment of constipation in Parkinson's disease. A randomized placebo-controlled study.

Authors:  Roberta Zangaglia; Emilia Martignoni; Margaret Glorioso; Maria Ossola; Giulio Riboldazzi; Daniela Calandrella; Gabriele Brunetti; Claudio Pacchetti
Journal:  Mov Disord       Date:  2007-07-15       Impact factor: 10.338

View more
  72 in total

1.  Concordance between severity of disease, prevalence of nonmotor symptoms, patient-reported quality of life and disability and use of medication in Parkinson's disease.

Authors:  Alberto Raggi; Matilde Leonardi; Venusia Covelli; Alberto Albanese; Paola Soliveri; Francesco Carella; Luigi Romito
Journal:  Neurol Sci       Date:  2011-11-10       Impact factor: 3.307

Review 2.  The Therapeutic Potential of Exercise to Improve Mood, Cognition, and Sleep in Parkinson's Disease.

Authors:  Gretchen O Reynolds; Michael W Otto; Terry D Ellis; Alice Cronin-Golomb
Journal:  Mov Disord       Date:  2015-12-30       Impact factor: 10.338

3.  Improved cognition while cycling in Parkinson's disease patients and healthy adults.

Authors:  Audrey A Hazamy; Lori J P Altmann; Elizabeth Stegemöller; Dawn Bowers; Hyo Keun Lee; Jonathan Wilson; Michael S Okun; Chris J Hass
Journal:  Brain Cogn       Date:  2017-01-11       Impact factor: 2.310

4.  Link between non-motor symptoms and cognitive dysfunctions in de novo, drug-naive PD patients.

Authors:  Roberto Erro; Gabriella Santangelo; Marina Picillo; Carmine Vitale; Marianna Amboni; Katia Longo; Angela Costagliola; Maria Teresa Pellecchia; Roberto Allocca; Anna De Rosa; Giuseppe De Michele; Lucio Santoro; Paolo Barone
Journal:  J Neurol       Date:  2012-02-07       Impact factor: 4.849

5.  Gastrointestinal dysfunction in Parkinson's disease.

Authors:  Michal Lubomski; Ryan L Davis; Carolyn M Sue
Journal:  J Neurol       Date:  2020-01-27       Impact factor: 4.849

6.  Neurophysiological investigation of auditory intensity dependence in patients with Parkinson's disease.

Authors:  Kim De Keyser; Miet De Letter; Patrick Santens; Durk Talsma; Dick Botteldooren; Annelies Bockstael
Journal:  J Neural Transm (Vienna)       Date:  2021-01-30       Impact factor: 3.575

7.  Mismatch negativity-like potential (MMN-like) in the subthalamic nuclei in Parkinson's disease patients.

Authors:  Eduard Minks; Pavel Jurák; Jan Chládek; Jan Chrastina; Josef Halámek; Daniel J Shaw; Martin Bareš
Journal:  J Neural Transm (Vienna)       Date:  2014-05-09       Impact factor: 3.575

8.  Attenuation of Endoplasmic Reticulum Stress, Impaired Calcium Homeostasis, and Altered Bioenergetic Functions in MPP+-Exposed SH-SY5Y Cells Pretreated with Rutin.

Authors:  Adaze Bijou Enogieru; William Lloyd Haylett; Hayley Christy Miller; Francois Hendrikus van der Westhuizen; Donavon Charles Hiss; Okobi Eko Ekpo
Journal:  Neurotox Res       Date:  2019-05-04       Impact factor: 3.911

9.  Use of Fourier-domain OCT to detect retinal nerve fiber layer degeneration in Parkinson's disease patients.

Authors:  M Satue; E Garcia-Martin; I Fuertes; S Otin; R Alarcia; R Herrero; M P Bambo; L E Pablo; F J Fernandez
Journal:  Eye (Lond)       Date:  2013-02-22       Impact factor: 3.775

Review 10.  Parkinson disease: an update.

Authors:  Steven J Frucht
Journal:  Neurologist       Date:  2004-07       Impact factor: 1.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.